Respiratory Tract Neoplasms 
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Respiratory Tract Neoplasms
NCT01731626: Pemetrexed Disodium and Cisplatin in Treating Patients Undergoing Surgery For Stage I-III Non-Small Cell Lung Cancer

Active, not recruiting
2
52
US
cisplatin, CACP, CDDP, CPDD, DDP, pemetrexed disodium, ALIMTA, LY231514, MTA, laboratory biomarker analysis, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, fludeoxyglucose F 18, 18FDG, FDG, therapeutic conventional surgery
Roswell Park Cancer Institute, National Cancer Institute (NCI), Eli Lilly and Company
Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
04/11
 
NCT01588028: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer

Checkmark In pts with crizotinib-resistant ALK-rearranged NSCLC
Aug 2014 - Aug 2014: In pts with crizotinib-resistant ALK-rearranged NSCLC
Checkmark WCLC 2013
Oct 2013 - Oct 2013: WCLC 2013
Checkmark ESMO-ECCO-ESTRO 2013
More
Active, not recruiting
1/2
36
US
CH5424802
Hoffmann-La Roche
ALK-Rearranged Non-Small Cell Lung Cancer
09/15
09/15
NCT01279798: Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

No Longer Available
N/A
US
Lucanix® (belagenpumatucel-L), Lucanix
NovaRx Corporation
Non-small Cell Lung Cancer
 
 
NCT02271139: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

No Longer Available
N/A
US
Alectinib
Genentech, Inc.
Non-Small Cell Lung Cancer
 
 

Download Options